CytoMed Therapeutics Limited filings document foreign private issuer disclosures for a clinical-stage cell therapy company. Form 6-K reports furnish clinical and regulatory updates for CAR γδ T cell, iPSC-derived γδ NKT cell, γδ T cell, and cord blood-derived Natural Killer cell programs, along with annual financial results and research expense disclosures.
The filing record also covers annual general meeting materials, proxy voting items, subsidiary structure changes, completed technology and asset acquisitions, non-dilutive subsidiary financing, and shareholder communication matters. These documents frame CytoMed's governance, capital resources, development spending, and corporate organization across Singapore and Malaysia.
For CytoMed Therapeutics Ltd, mDR LTD reported beneficial ownership of 1,191,523 ordinary shares, or 9.984% of the class. mDR LTD reported sole voting and dispositive power over those shares, with zero shared voting and dispositive power. The percentage is based on 11,934,908 issuer shares issued and outstanding as of June 30, 2026.
The reported holdings are based on 747,414 shares acquired through subscriptions between 2021 and 2022 and 589,509 shares issued upon conversion of a convertible loan in April 2023. mDR LTD also reported 145,400 shares sold between December 16, 2024 and October 12, 2026.
CytoMed Therapeutics Ltd (GDTC) Chairman and Director Choo Chee Kong reported purchasing 29,250 ordinary shares in open-market transactions on the Nasdaq Capital Market between October 12, 2026 and October 15, 2026. The purchases had a weighted average price of $0.8587 per share and an aggregate purchase price of approximately $25,117.35, paid through his brokerage account with personal funds.
Choo reported beneficial ownership of 3,003,996 ordinary shares, representing 25.17% of CytoMed’s outstanding shares. The reported total includes 2,075,310 shares held indirectly through Glorious Finance Limited, 194,112 held by EP Capital Inc., and 734,574 held directly. Choo owns a 55% stake in Glorious Finance and disclaims beneficial ownership of the remainder of its 3,773,291-share holding. The amendment says Choo and Glorious Finance’s remaining shareholders may be deemed to act as a group because they share voting and dispositive power over those shares, without a formal agreement governing voting or investment decisions.
CytoMed Therapeutics Ltd (GDTC) Chairman and Director Choo Chee Kong acquired 62,000 ordinary shares in open-market purchases on the Nasdaq Capital Market from October 5 through October 8, 2026, for an aggregate purchase price of approximately $60,554.03. He reported beneficial ownership of 2,974,746 ordinary shares, or 24.92% of the issuer’s outstanding ordinary shares, based on 11,934,908 shares outstanding as of the date hereof. The reported ownership includes 2,075,310 shares through Glorious Finance Limited, 194,112 shares held by EP Capital Inc., and 705,324 shares held directly. Choo owns a 55% stake in Glorious Finance and disclaims beneficial ownership of its remaining shares. The statement separately lists sole voting and dispositive power over 899,436 shares and shared voting and dispositive power over 3,773,291 shares.
On October 6, 2026, CytoMed Therapeutics Limited received a Nasdaq notice that its ordinary shares’ closing bid price had remained below the $1.00 per-share minimum bid price for 30 consecutive business days, from August 24 through October 5, 2026. The notice does not currently affect the shares’ Nasdaq listing or trading.
CytoMed has a 180-calendar-day period ending April 5, 2027 to regain compliance. Nasdaq will confirm compliance if the closing bid price is at least $1.00 per share for at least ten consecutive business days during that period. If CytoMed does not regain compliance by April 5, 2027, it may be eligible for an additional 180-day period, subject to Nasdaq staff determination and meeting the continued-listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market except the bid-price requirement. To qualify, it must give written notice of its intention to cure during the second period; its intended cure may include a reverse stock split if necessary. CytoMed says it is considering available options and intends to take reasonable measures to regain compliance.
CytoMed Therapeutics (GDTC) reported S$157,289 in revenue for the six months ended June 30, 2026, primarily from private blood banking services, versus S$155,887 a year earlier. Net loss narrowed approximately 20.1% to S$1.79 million (US$1.39 million), from S$2.25 million.
Net cash used in operating activities was S$1.65 million. Cash and bank balances were S$1.46 million at June 30, 2026, compared with S$2.10 million at December 31, 2025. Management believes current resources and offering proceeds will meet working-capital needs and capital expenditures for approximately the next year, but cautioned available capital could be exhausted sooner.
Financing activities generated S$963,664, including S$699,600 from a director loan and S$300,000 raised by a subsidiary from non-controlling interests. On September 29, 2026, the company entered into a shareholder loan agreement with a director for S$1 million, with a six-month tenure and 2.75% annual interest. Its ATM agreement permits sales up to an aggregate offering price of US$4.30 million; 99,123 shares had generated US$237,550 in gross proceeds as of September 30, 2026. The company has no therapeutic products approved for commercial sale. Its ANGELICA Phase I trial is at dose level 2, with recruitment expected to continue in the second half of 2026.
A proposed sale of 117,337 CytoMed Therapeutics Ltd (GDTC) ordinary shares was reported for mDR Ltd, identified as a 10% stockholder. The proposed sale has an aggregate market value of $103,256.56 and an approximate sale date of August 11, 2026. mDR Ltd held 1,221,523 ordinary shares immediately before the notice. Edward Lee Ewe Ming signed the notice.
CytoMed Therapeutics Ltd director and 10% owner Choo Chee Kong purchased 200,000 ordinary shares in July 2026 through two purchases in open market or private transactions at $1.50 per share on July 14 and July 20.
A Form 4/A amendment corrects the acquisition/disposition indicator to show these as acquisitions, and the Rule 10b5-1 box is unchecked, so the trades are not affirmed as made under a trading plan.
An amended ownership report for CytoMed Therapeutics Ltd shows that Chairman and Director Choo Chee Kong beneficially owns 2,899,746 ordinary shares, representing 24.30% of the issuer’s 11,934,908 ordinary shares outstanding as of the reported date.
The holdings comprise 2,075,310 shares deemed owned through Glorious Finance Limited, 194,112 shares through EP Capital Inc., and 630,324 shares held directly. He has sole voting and dispositive power over 824,436 shares and shared power over 3,773,291 shares. Between July 14 and July 20, 2026, he acquired 200,000 shares from Teoh Teik Kee at $1.50 per share, for $300,000, using personal funds via a brokerage account. The shares were obtained via capital contributions and open-market purchases for investment purposes. The disclosure notes that shareholders of Glorious Finance may be deemed a Section 13(d)(3) group due to shared voting and dispositive power, though there is no formal voting agreement.
CytoMed Therapeutics Ltd director and 10% owner Choo Chee Kong reported two non-derivative transactions in ordinary shares of CytoMed Therapeutics Limited. On July 20, 2026 and July 14, 2026, he recorded dispositions of 100,000 shares each at $1.50 per share. Both transactions are classified as direct ownership, and no post-transaction share balance is reported in this disclosure.
CytoMed Therapeutics Limited reports that Chairman and Director Choo Chee Kong has offered to acquire up to 200,000 company shares from independent arm’s-length shareholders through private cash transactions, with a stated minimum acquisition of 100,000 shares. The company is not a party to these trades and receives no proceeds.
Separately, Mr. Choo, via his wholly owned entity EP Capital Inc., invested S$300,000 (approximately US$250,000) into subsidiary LongevityBank Pte Ltd. This increases EP Capital’s stake in LongevityBank from 6.4% to 12.0%, based on a S$5 million post-money valuation. LongevityBank plans to use the funds to establish a research and development laboratory to support product innovation and improve processes alongside the company’s existing cGMP manufacturing facility.